Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20

References

• European Centre for Disease Prevention and Control. Invasive pneumococcal disease. Annual epidemiological report for 2018. 2018 [cited 2020 Sept 14]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_IPD.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Surveillance and reporting 2017 [2019 Apr 3]. Available from: https://www.cdc.gov/pneumococcal/surveillance.html
   Google Scholar
• Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45–51.
   PubMed Web of Science ®Google Scholar
• Suaya JA, Gessner BD, Fung S, et al. Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011–2016. Vaccine 2018;36(49):7479–7486.
   PubMed Web of Science ®Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. The Lancet Global Health. 2018;6(7):e744–e757.
   PubMed Web of Science ®Google Scholar
• Myint TT, Madhava H, Balmer P, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30(2):127–151.
   PubMed Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007;298(15):1772–1778.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLOS Med. 2013;10(9):e1001517.
   PubMed Web of Science ®Google Scholar
• Matanock A, Lee G, Gierke R, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069–1075.
   PubMed Web of Science ®Google Scholar
• Pichichero M, Kaur R, Scott DA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018;2(8):561–568.
   PubMedGoogle Scholar
• Savulescu C, Krizova P, Lepoutre A, et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respir Med. 2017;5(8):648–656.
   PubMed Web of Science ®Google Scholar
• Bonnave C, Mertens D, Peetermans W, et al. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe. Eur J Clin Microbiol Infect Dis. 2019;38(4):785–791.
   PubMed Web of Science ®Google Scholar
• Varghese J, Chochua S, Tran T, et al. Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clin Microbiol Infect. 2020;26(4):e511–512.
   Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451.
   PubMed Web of Science ®Google Scholar
• Pick H, Daniel P, Rodrigo C, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18. Thorax. 2020;75(1):38–49.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Rodgers GL. Time for a third-generation pneumococcal conjugate vaccine. Lancet Infect Dis. 2020;21(1):14–16.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–309.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. VAXNEUVANCE™ (pneumococcal 15-valent conjugate vaccine) prescribing information 2021. 2021 [cited 2021 Jul 21]. Available from: https://www.fda.gov/media/150819/download
   Google Scholar
• Food and Drug Administration. PREVNAR 20 (pneumococcal 20-valent conjugate vaccine) prescribing information 2021. 2021 [cited 2021 Jul 26]. Available from: https://www.fda.gov/media/149987/download
   Google Scholar
• Es-Skali IJ, and Spoors J. Analysis of indirect treatment comparisons in national health technology assessments and requirements for industry submissions. J Comp Eff Res. 2018;7(4):397–409.• Reference of interest as it highlights relevance and value of indirect treatment comparisons when head-to-head data are not available.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Adegbola RA. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert Rev Vaccines. 2015;14(3):413–428.
   PubMed Web of Science ®Google Scholar
• Platt HL, Cardona JF, and Haranaka M, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2021;In press doi:https://doi.org/10.1016/j.vaccine.2021.08.049. Sep 7;S0264-410X(21)01097-5. • Reference of interest as it describes results for a study included in the indirect comparison.
   Google Scholar
• Song J-Y, Chang C-J, and Andrews C, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: a randomized phase III trial (PNEU-PATH). Vaccine. 2021;39(43) 6422–6436 .
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Lot-to-lot consistency of V114 in healthy adults (V114-020) (PNEU-TRUE) 2021.2021 [cited 2021 Jul 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03950856.• Reference of interest as it describes results for a study included in the indirect comparison
   Google Scholar
• Simon JK. A phase III, randomised, double-blind, active comparator-controlled, lot-to-lot consistency study to evaluate the safety and immunogenicity of V114 in healthy adults ≥50 years of age (PNEU-TRUE). Presented at: 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2021 July 9–12.• Reference of interest as it describes results for a study included in the indirect comparison.
   Google Scholar
• Essink B, Sabharwal C, and Xu X, et al. Phase 3 pivotal evaluation of 20-valent pneumococcal conjugate vaccine (PCV20) safety, tolerability, and immunologic noninferiority in participants 18 years and older. Presented at: IDWeek (Infectious Diseases Society of America); 2020 October 21–25.• Reference of interest as it describes results for a study included in the indirect comparison.
   Google Scholar
• Vakevainen M, Jansen W, Saeland E, et al. Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable? Clin Diagn Lab Immunol. 2001;8(2):363–369.
   PubMedGoogle Scholar
• Song JY, Moseley MA, Burton RL, et al. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013;19(3):412–425.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Correlates of vaccine-induced protection: methods and implications 2013 [2021 Aug 25]. Available from: https://apps.who.int/iris/bitstream/handle/10665/84288/WHO_IVB_13.01_eng.pdf
   Google Scholar
• Rose CE, Romero-Steiner S, Burton RL, et al. Multilaboratory comparison of streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin Vaccine Immunol. 2011;18(1):135–142.
   PubMedGoogle Scholar
• Clinicaltrials.gov. Trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 2020 [cited 2021 Jul 26]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03760146.
   Google Scholar
• Nolan KM, Bonhomme ME, Schier CJ, et al. Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes. Bioanalysis 2020;12(14):1003–1020.
   PubMed Web of Science ®Google Scholar
• Burton RL, Antonello J, Cooper D, et al. Assignment of opsonic values to pneumococcal reference serum 007sp for use in opsonophagocytic assays for 13 serotypes. Clin vaccin immunol. 2017;24(2). DOI:https://doi.org/10.1128/CVI.00457-16.
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013;31(35):3577–3584.
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine. 2014;32(20):2364–2374.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with Adalimumab or etanercept. Pharmacoeconomics 2010;28(10):935–945.
   PubMed Web of Science ®Google Scholar
• Bryant KA, Frenck R, Gurtman A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18–49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. Vaccine 2015;33(43):5854–5860.
   PubMed Web of Science ®Google Scholar
• Fink AL, Klein SL. Sex and gender impact immune responses to vaccines among the elderly. Physiology (Bethesda). 2015;30:408–416.
   PubMed Web of Science ®Google Scholar
• Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhyā Indian J Stat. 2000;62:134–148.
   Google Scholar
• Cui YA, Patel H, O’Neil WM, et al. Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world. Hum Vaccin Immunother. 2017;13(6):1–13.
   Web of Science ®Google Scholar
• Grant LR, O’Brien SE, Burbidge P, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One. 2013;8(9):e74906.
   PubMed Web of Science ®Google Scholar
• Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization; a randomized double-blind trial. Clin Infect Dis. 2013;57(7):952–962.
   PubMed Web of Science ®Google Scholar
• Stoecker C. Economic assessment of PCV15 & PCV202021. 2021 Jul 27. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-Pneumococcal-Stoecker-508.pdf
   Google Scholar
• Park DE, Johnson TS, Nonyane BA, et al. The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. Pediatr Infect Dis J. 2014;33(Suppl 2):S130–139.
   PubMed Web of Science ®Google Scholar